while EGFR can also be phosphorylated by Src at several phosphorylation sites (2, 18).
87
Furthermore, Src is required for EGFR transactivation by cytokines and other stimuli (1, 19).
88
In this signaling cascade, membrane-bound EGFR proligands are cleaved by proteases, such 89 as tumor necrosis factor-α-converting enzyme (TACE), and bind to EGFR, enabling them to 90 activate downstream signaling pathway (46).
91
In the present study, we report that LPS induces EGFR activation through Csk / Src, 92 leads to RhoA / Rho-kinase activation and disrupts directional migration of myofibroblast. 
109
Drug administration in vivo. LPS and erlotinib were injected into the amniotic sac in 110 accordance with previous methods (30). Briefly, LPS (1μg, 0.2μg/μl) with or without erlotinib 111 (50μg) was injected into the amniotic sac of pregnant rats at 16.5 days post coitum (E16.5).
112
Rats injected with saline (sterile, endotoxin-free) were used as control. The day pups were 113 born was counted as postnatal day (P0) and newborn rats were euthanized at P7 for further 114 investigation. antibodies for 1h followed by incubation with Acti-stain 488 phalloidin (100 nM).
173
RhoA pull-down assay and Csk activity assay. To assess RhoA activation, RhoA pull-down 174 assays were performed to isolate the active GTP-bound form using RhoA activation assay kits
175
(Cytoskeleton, Denver, CO) following the manufacturer's protocol. To assess Csk activity, 176 myofibroblasts were collected and equal amounts of protein extracts were subjected to Csk 177 activity assay with a spectrophotometric determination kit (Genmed, Shanghai, China). Csk 178 activity was calculated according to a formula provided by the manufacturer.
179
TACE activity assay. Cultured myofibroblasts were analyzed for TACE activity using can be monitored at excitation/emission = 490 nm/520 nm.
186
Immunostaining. For immunohistochemistry, paraffin-embedded lung sections were lysed. Proteins were resolved by SDS-PAGE and transferred onto nitrocellulose membranes.
197
The membranes were blocked with T-TBS containing 5% nonfat milk and probed with 
Results

210
LPS disrupted directional migration of myofibroblasts
211
To investigate the effect of LPS on directional migration of myofibroblasts, Golgi 212 polarization assays and transwell migration assays were applied. No obvious wound closure 213 was observed after 6 hours following wounding in each group of Golgi polarization assays.
214
Cultured myofibroblasts treated with LPS exhibited significantly reduced Golgi reorientation 215 toward the wound compared with PBS treatment (Fig. 1B) because it has been documented to be involved in Src-mediated EGFR transactivation (46).
263
Results show that LPS stimulated a twofold increase of TACE activity, which was blocked by 264 the Src inhibitor PP1 (Fig. 4J ).
265
The effect of EGFR on myofibroblast migration was mediated through RhoA activation.
266
Considering the established role of RhoA in cell migration (12), we investigated the 267 contribution of RhoA to cell migration in our cell system. RhoA activation was detected using 268 a pull-down assay that specifically recognizes the active, GTP-bound form. As shown in Fig.   269 11 5A, LPS treatment increased RhoA activation. Similarly, rhTGF-α also stimulated RhoA 270 activation in cultured myofibroblasts (Fig. 5B) . In addition, EGFR-antagonism with AG1478
271
blocked LPS-or TGF-α-induced RhoA activation (Fig. 5A, B) . Furthermore, LPS or TGF-α 272 treated cells showed a significant reduction in directional migration, which was restored by 273 the Rho-associated kinase (ROCK) inhibitor Y-27632 (Fig. 5C, D) . Interestingly, we also (1), 2) junction of secondary septa and primary septa (2) and 3) secondary septa (3) (Fig. 6C ).
290
Compared with the saline group, LPS treatment resulted in fewer myofibroblasts in secondary 291 septa and more accumulation in the primary septa, while treatment with erlotinib effectively 292 alleviated the abnormal localization of myofibroblasts at P7 (Fig. 6B) 
364
Cell migration is a highly integrated, muti-step process, including formation of stable importantly, the EGFR inhibitor erlotinib provides therapeutic benefit in LPS-injected rats.
394
These results suggest that this pathway may be a promising target for BPD treatment. were treated with rhTGF-α (1ng/ml) for 6h before Golgi polarization was determined and 598 myofibroblasts were allowed to migrate for 24h in the presence of rhTGF-α prior to 599
